BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30171453)

  • 1. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
    Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
    Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
    Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
    Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
    Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
    Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
    Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
    Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
    Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of primary central nervous system lymphoma.
    Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K
    Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
    Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
    Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular diagnostics for vitreoretinal lymphoma].
    Bonzheim I; Salmerón-Villalobos J; Süsskind D; Szurman P; Gekeler F; Spitzer MS; Salaverria I; Campo E; Coupland SE; Quintanilla-Martinez L; Fend F
    Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):150-154. PubMed ID: 37947807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.
    Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G
    Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
    Vater I; Montesinos-Rongen M; Schlesner M; Haake A; Purschke F; Sprute R; Mettenmeyer N; Nazzal I; Nagel I; Gutwein J; Richter J; Buchhalter I; Russell RB; Wiestler OD; Eils R; Deckert M; Siebert R
    Leukemia; 2015 Mar; 29(3):677-85. PubMed ID: 25189415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma.
    He J; Wu J; Jiao Y; Rodriguez FJ; Blakeley JO; Kinzler KW; Papadopoulos N; Vogelstein B; Holdhoff M
    J Neurooncol; 2013 Sep; 114(3):275-9. PubMed ID: 23828278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
    Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
    World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic characterization of primary central nervous system lymphoma.
    Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
    Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
    Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.
    Downs BM; Ding W; Cope LM; Umbricht CB; Li W; He H; Ke X; Holdhoff M; Bettegowda C; Tao W; Sukumar S
    Clin Epigenetics; 2021 May; 13(1):104. PubMed ID: 33952317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.